Intradigm (Palo Alto, CA) early-stage developer of RNAi-based oncology therapeutics, closed a $18.5M Series B financing. Participants include Lilly Ventures, Roche Venture Fund, MP Healthcare Venture Management, Frazier Healthcare Ventures, Alta Partners, MediBic Alliance Technology Fund and Novartis Venture Fund.